

In re Application of:
Evans et al.
Application No.: 08/931,694
Filed: September 16, 1997
Page 2

PATENT
Attorney Docket No.: SALK1280-4


In The Claims

B³
Please cancel claims 2-4 and 9-15 without prejudice and amend claim 1 as follows:

B¹
B²
1. (Amended) A method for the treatment of ~~[a subject afflicted with]~~ a steroid or steroid-like hormone-responsive disease state in a subject in need thereof, said method comprising administering to said subject an effective amount of a ligand which selectively interacts with the receptor subtype associated with said steroid or steroid-like hormone responsive disease state, to a significantly greater extent than with other subtypes of the same receptor class.

Please add new claims 16-18 as follows:


~~6.~~ (New) A method according to Claim ⁵ wherein said RAR- α selective ligand is the amide:




In re Application of:
Evans et al.
Application No.: 08/931,694
Filed: September 16, 1997
Page 3

PATENT
Attorney Docket No.: SALK1280-4

(New) A method according to Claim 8 wherein said RAR- β selective ligand is the phenyl-naphthyl derivative:



or benzophenone derivative:



18. (New) A method according to Claim 8 wherein said RAR- γ selective

ligand is the phenyl-naphthyl derivative:

12/98

